The Food and Drug Administration (FDA) announced this summer's meeting to review the potential loosening of restrictions on several widely-used peptides, many of which lack FDA approval or extensive safety testing. This move follows commitments by Health Secretary RFK Jr. to relax peptide regulations, advocating for their use in muscle building, injury healing, and anti-aging, despite limited scientific backing. The FDA intends to consult an external advisory panel to decide whether these peptides can be safely produced by pharmacies, and plans to remove some from high-risk drug lists in the process.

Peptides, which are biological building blocks linked to hormones that regulate growth and healing, have gained popularity in wellness circles, especially with the success of FDA-approved peptides for diabetes and obesity. However, many substances like BPC-157 and TB-500 remain unapproved, marketed online without proven safety or efficacy, and are banned in professional sports. Critics warn that easing regulations could pose serious health risks and undermine the FDA’s longstanding drug approval system. The decision has generated concern among public health experts, who fear it may lead to a proliferation of unregulated and potentially unsafe products, fueled further by industry pressures and political influence.